Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 20/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.78 |
| ▸ | ACACA | Q13085 | 6/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050701 | 0.92 | ACACB (0.80) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050694 | 0.92 | ACACB (0.79) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050699 | 0.92 | ACACB (0.83) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050700 | 0.90 | ACACB (0.75) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050598 | 0.89 | ACACB (0.80) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050693 | 0.89 | ACACB (0.79) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050696 | 0.89 | ACACB (0.79) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050684 | 0.88 | ACACB (0.86) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050612 | 0.88 | ACACB (0.78) | ACACBCYP2C9ACACACYP2C19CYP3A4 | |
| SCHEMBL17050695 | 0.88 | ACACB (0.78) | ACACBCYP2C9ACACACYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885CYP2C9 524/4885ACACA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.